About Covantage Therapeutics
Covantage Therapeutics is a next-generation biotechnology company focused on accelerating the discovery and development of innovative cancer therapies. We combine advanced artificial intelligence with deep biological and chemical expertise to help transform promising scientific discoveries into development-ready drug programs.
Our Vision
Our mission is simple but ambitious: to dramatically shorten the path from discovery to therapy. By compressing discovery timelines, reducing development risk, and improving clinical success rates, we aim to help bring new treatments to patients facing serious and underserved diseases.
What We Offer
Novel Drug Discovery &
Development
We deliver deep, AI-driven understanding of cancer biology by integrating multi-omics data, patient genomics, clinical chemistry, and disease biology into a unified intelligence layer. Our platform systematically maps mutations, signalling pathways, and molecular networks to identify high-confidence targets, clinically relevant biomarkers, and disease-specific vulnerabilities. By contextualizing genomic data with real biological and clinical evidence, we transform complex datasets into actionable insights that guide precision therapy development, patient stratification, and indication selection.
- Target identification & Validation
- Drug Repurposing & Combinations
- Drug Repositioning
- Biomarker Profiling
- Patient Stratification
- Indication Selection
- Companion Diagnostics
- Virtual Clinical Trials
AI-Integrated Mechanistic Biology & Clinical Chemistry Platform validated in our Preclinical Development
Our AI-powered discovery engine bridges computational prediction with rigorous preclinical science. We enable rational drug repurposing, novel target Identification, validation, and mechanism-of-action driven molecule prioritization through virtual screening, toxicity profiling, and predictive efficacy modeling. These insights are seamlessly translated into in-vitro and in-vivo validation using disease-relevant models, ensuring early go/no-go decisions are grounded in biology. This integrated approach reduces attrition, accelerates timelines, and significantly lowers development risk before entering costly clinical stages.
- Virtual Screening (In-Vitro)
- Virtual Screening (In-Vivo)
- Toxicology Profiling/ Virtual Screening
- Cardiotoxicity screening
- Carcinogenicity screening
- Hepatotoxicity
- Neurotoxicity
- Allergic Reactions and Side Effects Matrix
- Preclinical Development including LI/LO and IND enabling studies.
Translational & Clinical Development Acceleration
We extend discovery insights into the clinic through translational intelligence that links molecular biology to patient outcomes. Our platform supports virtual clinical trials, companion diagnostics development, and rational drug-combination strategies to optimize clinical success. By aligning biomarkers, patient selection, and therapeutic hypotheses early, we help partners minimize clinical failure rates, shorten development cycles, and achieve meaningful differentiation in competitive therapeutic landscapes.
- Virtual Clinical Trials and data validation to identify right patient for right Trials
- Inclusion/Exclusion Development
- Companion Diagnostics
- Drug Combination Trials
- Biomarker Validation
Why Partner with Covantage
A New Model for Accelerating Therapeutic Discovery
Covantage combines advanced AI, deep biological insight, and rigorous experimental validation to accelerate the development of high-confidence therapeutic programs.
Integrated AI + Experimental Biology
Our platform unifies computational discovery with real-world laboratory validation, creating a continuous learning loop between data, models, and experiments.
- AI-driven multi-omics analysis
- Predictive modeling of disease biology
- Rapid in-vitro and in-vivo validation
End-to-End Development Capability
From molecular insight to development-ready programs, Covantage provides the infrastructure required to translate discovery into therapeutics.
- Target discovery and validation
- Mechanistic biology and biomarker identification
- Preclinical development and IND-ready packages
Focus on High-Impact Diseases
We focus our capabilities where scientific innovation can make the greatest difference for patients.
- Oncology
- Autoimmune disease
- CNS disorders
Partnership-Driven Model
Covantage works closely with academic researchers, biotech innovators, and pharmaceutical partners to transform promising discoveries into development-ready therapeutic programs.
- Academic collaboration
- Biotech program acceleration
- Pharma partnership and co-development